Humacyte, Inc. (HUMA)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenue | 301 | 517 | - | - |
| Selling, general and administrative | 7,809 | 8,136 | - | - |
| Research and development | 22,006 | 15,418 | 22,926 | 23,753 |
| Cost of goods sold | 213 | 147 | - | - |
| Total operating expenses | 30,028 | 23,701 | - | - |
| General and administrative | - | - | 7,307 | 5,746 |
| Total operating expenses | - | - | 30,233 | 29,499 |
| Loss from operations | -29,727 | -23,184 | -30,233 | -29,499 |
| Change in fair value of derivatives | -748 | 14,930 | 1,047 | -388 |
| Interest income | 832 | 662 | 911 | 1,310 |
| Interest expense | 2,545 | 3,000 | 2,438 | 2,515 |
| Change in fair value of contingent earnout liability | 5,470 | -49,731 | 8,489 | 25,571 |
| Total other income (expense), net | -7,931 | 62,323 | -8,969 | -27,164 |
| Net income (loss) | -37,658 | 39,139 | -39,202 | -56,663 |
| Net income (loss) per share attributable to common stockholders, basic (in dollars per share) | -0.24 | 0.28 | -0.33 | -0.48 |
| Net income (loss) per share attributable to common stockholders, diluted (in dollars per share) | -0.24 | 0.28 | -0.33 | -0.48 |
| Weighted-average shares outstanding used in computing net income (loss) per share attributable to common stockholders, basic (in shares) | 155,437,281 | 131,496,877 | 119,408,565 | 119,174,681 |
| Weighted-average shares outstanding used in computing net income (loss) per share attributable to common stockholders, diluted (in shares) | 155,437,281 | 131,759,302 | 119,408,565 | 119,174,681 |